Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/30/20
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple MyelomaBusiness Wire • 07/29/20
bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene TherapyThe Motley Fool • 06/12/20
Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/25/20
bluebird (BLUE): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 05/15/20
Biotech Stock Dives After FDA Rejects Its Bristol-Partnered Cancer DrugInvestors Business Daily • 05/13/20
bluebird bio, Inc. (BLUE) CEO Nick Leschly on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?Zacks Investment Research • 05/08/20
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be PrematureThe Motley Fool • 04/01/20
Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/19/20